In this episode of "The Top Line," Annalee Armstrong and Gabrielle Masson shine a spotlight on some of the most promising companies in the biotech world. Additionally, you'll have the opportunity to hear from Kevin Dunleavy as he engages in a conversation with Ray Pressburger from Accenture, discussing drug commercialization and the models that are proving to be the most effective.

In this episode of "The Top Line," Annalee Armstrong and Gabrielle Masson shine a spotlight on some of the most promising companies in the biotech world. Additionally, you'll have the opportunity to hear from Kevin Dunleavy as he engages in a conversation with Ray Pressburger from Accenture, discussing drug commercialization and the models that are proving to be the most effective.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Fierce Biotech's Fierce 15, plus a deep dive into drug commercialization strategies

Since Xaira’s eye-popping $1 billion fundraise in 2024, the company has said relatively little in public. That’s made it one of biotech’s more closely watched black boxes: a company with enormous backing, enormous ambition and, until recently, few clues about what it has actually been building.

In this week’s episode of “The Top Line,” Fierce Biotech’s Gabrielle Masson speaks with Xaira Chief Operating Officer Jeff Jonker about what the AI company is uncovering. Jonker discusses Xaira’s strategy as a next-generation biotech, the modalities and disease areas it is exploring, what he expects the industry to look like over the next five years and why Xaira is going after the “high-hanging fruit.”

To learn more about the topics in this episode: 
Xaira exec divulges R&D focus, how $1B fundraise fuels AI-driven hunt for what the 'industry is hungriest for'
New AI drug discovery powerhouse Xaira rises with $1B in funding
Biotech's top money raisers of 2024

Since Xaira&rsquo;s eye-popping $1 billion fundraise in 2024, the company has said relatively little in public. That&rsquo;s made it one of biotech&rsquo;s more closely watched black boxes: a company with enormous backing, enormous ambition and, until recently, few clues about what it has actually been building.
In this week&rsquo;s episode of &ldquo;The Top Line,&rdquo; Fierce Biotech&rsquo;s Gabrielle Masson speaks with Xaira Chief Operating Officer Jeff Jonker about what the AI company is uncovering. Jonker discusses Xaira&rsquo;s strategy as a next-generation biotech, the modalities and disease areas it is exploring, what he expects the industry to look like over the next five years and why Xaira is going after the &ldquo;high-hanging fruit.&rdquo;
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/xaira-exec-divulges-rd-focus-how-ai-company-chasing-what-industry-hungriest">Xaira exec divulges R&amp;D focus, how $1B fundraise fuels AI-driven hunt for what the 'industry is hungriest for'</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/new-ai-drug-discovery-powerhouse-xaira-rises-1b-funding">New AI drug discovery powerhouse Xaira rises with $1B in funding</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/biotechs-top-money-raisers-2024">Biotech's top money raisers of 2024</a></li>
</ul>

What Xaira is building after its $1B fundraise

In this week’s episode of “The Top Line,” we take a deep dive into the fourth-quarter performance of the biopharma industry and how the sector fared in 2025 overall.

As the world’s 25 largest biopharma companies reported earnings, attention quickly shifted to their outlook for 2026. Only five drugmakers expect faster growth than in 2025, and some are projecting sales declines.

One of the most surprising outlooks came from Novo Nordisk, which expects a significant drop in sales. Several other companies are also facing the loss of patent protection for blockbuster drugs, leading them to forecast either declining revenue or slower growth.

Fierce Pharma’s Kevin Dunleavy and Eric Sagonowsky discuss the trends emerging from fourth-quarter earnings and how the industry’s performance compares with previous quarters. They also examine the intensifying GLP-1 competition between Novo Nordisk and Eli Lilly and how the two companies appear to be heading in opposite directions.

To learn more about the topics in this episode: 

Eli Lilly, Novo Nordisk lead revenue boom in the 'always tricky' Q4
As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026
Biopharma industry gathers momentum in Q3
In Q3, drugmakers saw a marked decline in US vaccine sales as Eli Lilly kicked into higher gear

In this week&rsquo;s episode of &ldquo;The Top Line,&rdquo; we take a deep dive into the fourth-quarter performance of the biopharma industry and how the sector fared in 2025 overall.
As the world&rsquo;s 25 largest biopharma companies reported earnings, attention quickly shifted to their outlook for 2026. Only five drugmakers expect faster growth than in 2025, and some are projecting sales declines.
One of the most surprising outlooks came from Novo Nordisk, which expects a significant drop in sales. Several other companies are also facing the loss of patent protection for blockbuster drugs, leading them to forecast either declining revenue or slower growth.
Fierce Pharma&rsquo;s Kevin Dunleavy and Eric Sagonowsky discuss the trends emerging from fourth-quarter earnings and how the industry&rsquo;s performance compares with previous quarters. They also examine the intensifying GLP-1 competition between Novo Nordisk and Eli Lilly and how the two companies appear to be heading in opposite directions.
To learn more about the topics in this episode:&nbsp;
<ul>
<li>
<ul>
<li><a href="https://www.fiercepharma.com/pharma/eli-lilly-novo-nordisk-lead-revenue-boom-always-tricky-fourth-quarter">Eli Lilly, Novo Nordisk lead revenue boom in the 'always tricky' Q4</a></li>
<li><a href="https://www.fiercepharma.com/pharma/while-lilly-continues-boom-q4-many-other-drugmakers-are-projecting-slide-26">As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026</a></li>
<li><a href="https://www.fiercepharma.com/pharma/biopharma-industry-gathers-momentum-q3">Biopharma industry gathers momentum in Q3</a></li>
<li><a href="https://www.fiercepharma.com/pharma/q3-drugmakers-saw-marked-decline-vaccine-sales-especially-us">In Q3, drugmakers saw a marked decline in US vaccine sales as Eli Lilly kicked into higher gear</a></li>
</ul>
</li>
</ul>

Patent expirations push biopharma industry toward a tougher 2026

The design of the modern R&D lab may be due for a rethink.

Artificial intelligence and automation are reshaping how science gets done, yet many of the physical spaces where research happens were built around assumptions that date back decades.

In this episode of “The Top Line,” Fierce Life Sciences & Healthcare Editor-in-Chief Ayla Ellison speaks with Gensler Global Sciences Practice Area Leader Ryley Poblete about how automation, data and new research workflows are influencing lab design. As computational scientists, engineers and automated systems become more central to research teams, organizations are reconsidering how labs should be structured to support both focused work and collaboration across disciplines.

 

The design of the modern R&amp;D lab may be due for a rethink.
Artificial intelligence and automation are reshaping how science gets done, yet many of the physical spaces where research happens were built around assumptions that date back decades.
In this episode of &ldquo;The Top Line,&rdquo; Fierce Life Sciences &amp; Healthcare Editor-in-Chief Ayla Ellison speaks with Gensler Global Sciences Practice Area Leader Ryley Poblete about how automation, data and new research workflows are influencing lab design. As computational scientists, engineers and automated systems become more central to research teams, organizations are reconsidering how labs should be structured to support both focused work and collaboration across disciplines.
&nbsp;

Fierce Biotech's Fierce 15, plus a deep dive into drug commercialization strategies

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips